Clinical Trials Logo

Hyperphosphatemia clinical trials

View clinical trials related to Hyperphosphatemia.

Filter by:

NCT ID: NCT01852682 Completed - Hyperphosphatemia Clinical Trials

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

NCT ID: NCT01850641 Completed - Hemodialysis Clinical Trials

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Start date: April 29, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.

NCT ID: NCT01850602 Completed - Hemodialysis Clinical Trials

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Start date: April 23, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia

NCT ID: NCT01833494 Completed - Clinical trials for Hemodialysis Patients With Hyperphosphatemia

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Start date: March 18, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

NCT ID: NCT01755078 Completed - Hemodialysis Clinical Trials

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.

NCT ID: NCT01742611 Completed - Clinical trials for Chronic Kidney Disease

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start date: March 2013
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.

NCT ID: NCT01742585 Completed - Clinical trials for Chronic Kidney Disease

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.

NCT ID: NCT01696279 Completed - Clinical trials for Chronic Kidney Disease

A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis

Start date: February 15, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to summarize the percentage of participants achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus in hyperphosphatemic children and adolescents with chronic kidney disease (CKD) who are on dialysis, following 8 weeks of treatment with lanthanum carbonate.

NCT ID: NCT01578200 Completed - Hemodialysis Clinical Trials

Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study

LANDMARK
Start date: December 24, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate decrease in cardiovascular mortality and morbidity in Japanese hemodialysis patients treated with Lanthanum carbonate compared with those with Calcium carbonate.

NCT ID: NCT01574326 Completed - Clinical trials for Chronic Kidney Disease

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease

Start date: May 2012
Phase: Phase 2
Study type: Interventional

Objective: In hyperphosphatemic pediatric patients with chronic kidney disease (CKD) to - Evaluate the safety and tolerability of sevelamer carbonate - Evaluate the efficacy of sevelamer carbonate on the control of serum phosphorus